21 February 2022
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Grant of Options and PDMR Dealing
Ondine Biomedical Inc. (AIM: OBI), announces the grant of options to acquire, in aggregate, up to 600,000 common shares (the "Options").
Options to acquire up to 600,000 shares have been granted pursuing to the Ondine Company Share Option Plan. The Options will vest evenly over four years, starting immediately and fully vesting on 4 February 2026. The Options will be exercisable throughout the vesting period and until the 4 February 2027, at a price of £0.54 per new ordinary share.
The Options has been granted to Charles Young, the Company's Vice President Sales & Marketing, North America, and to William Kanz, Vice President Engineering, and the notification below, made in accordance with the UK Market Abuse Regulation, provides further details in this regard.
| PDMR |
Position |
Number of Shares Under Option |
Exercise Price |
Vesting Date |
Expiry Date |
| Charles Young |
Vice President Sales & Marketing, North America |
400,000 |
£0.54 |
Fully vested February 4, 2026 |
February 4, 2027 |
| William Kanz |
Vice President Engineering |
200,000 |
£0.54 |
Fully vested February 4, 2026 |
February 4, 2027 |
Following the grant of the Options, the Company has options outstanding over a total of 8,098,000 shares, which represent approximately 4.2% of the Company's existing issued ordinary share capital.
For further Information, contact:
Ondine Biomedical Inc.
Carolyn Cross, CEO
Telephone: +1 604 669 0555
Arden Partners plc
Nominated Adviser and Broker
Ruari McGirr / Antonio Bossi
Telephone: +44 (0)20 7614 5900
Media Contact:
Simon Vane Percy
Telephone: +44 (0)7710005910
Email: simon@vanepercy.com / amanda@vanepercy.com
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
| a) |
Name |
Charles Young
|
||||
| 2 |
Reason for the notification |
|||||
| a) |
Position/status |
Vice President Sales & Marketing, North America
|
||||
| b) |
Initial notification /Amendment |
Initial Notification
|
||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
| a) |
Name |
Ondine Biomedical Inc.
|
||||
| b) |
LEI |
9845005B69E07CGF4A56
|
||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
| a)
|
Description of the financial instrument, type of instrument Identification code |
Stock Options for Ordinary Shares
|
||||
| b) |
Nature of the transaction |
Grant of share option under the Ondine Biomedical Company Share Option Plan
|
||||
| c)
|
Price(s) and volume(s)
|
|
||||
| d) |
Aggregated information - Aggregated volume - Price |
N/A - single transaction |
||||
| e) |
Date of the transaction |
February 17, 2022
|
||||
| f) |
Place of the transaction |
Outside of a trading venue
|
||||
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
| a) |
Name |
William Kanz
|
||||
| 2 |
Reason for the notification |
|||||
| a) |
Position/status |
Vice President Engineering
|
||||
| b) |
Initial notification /Amendment |
Initial Notification
|
||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
| a) |
Name |
Ondine Biomedical Inc.
|
||||
| b) |
LEI |
9845005B69E07CGF4A56
|
||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
| a)
|
Description of the financial instrument, type of instrument Identification code |
Stock Options for Ordinary Shares
|
||||
| b) |
Nature of the transaction |
Grant of share option under the Ondine Biomedical Company Share Option Plan
|
||||
| c)
|
Price(s) and volume(s)
|
|
||||
| d) |
Aggregated information - Aggregated volume - Price |
N/A - single transaction |
||||
| e) |
Date of the transaction |
February 17, 2022
|
||||
| f) |
Place of the transaction |
Outside of a trading venue
|
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.